Why Agilent Technologies (A) Stock Is Up Today

Agilent Technologies (A) launched the S540MD slide scanner in the U.S., capable of holding 540 slides, targeting high-volume pathology labs. The scanner has FDA clearance and integrates with existing lab setups. Agilent reported Q3 revenue of $1.88B, up 8.1% YoY, and raised full-year non-GAAP EPS guidance to $6.18-$6.21. The scanner is a rebadged Hamamatsu model, with no pricing or revenue estimates provided.

Agilent Technologies (A) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. The Zacks rating system, which is based on earnings estimate revisions, suggests a positive outlook for the company's stock price. Analysts have raised their estimates for Agilent by 3.4% over the past three months, with the company expected to earn $6.17 per share for the fiscal year ending October 2026.

Agilent (A) acquired Biocare for $950M. The company reported Q3 earnings, with shifts in debt and other financial metrics. The deal expands Agilent's diagnostics portfolio.

Agilent (A) reported Q3 2026 revenue of $1.88B, up 7.3% and exceeding guidance. EPS was $1.56, up 14% YoY. Strong performance driven by pharma, China growth, and Ignite strategy. Key growth areas include pharma, semiconductors, and AI infrastructure.

Agilent Technologies (A) reported Q3 2026 sales of $1.88B and net income of $362M, with EPS rising to $1.28. The company raised its full-year revenue and profit guidance, citing strong demand in pharma, China, and advanced materials, plus cost savings from its Ignite program. The updated outlook suggests margin benefits and product launches are offsetting cost pressures. Investors should note ongoing tariff and supply chain risks. Analysts' fair value estimates for Agilent range from $150.54 to

TD Cowen raised its target price for Agilent Technologies Inc. to $180 from $155. The article also discusses Webull's trading services and risks, including SIPC protection and margin trading details.